BiologicTx® Appoints Dr. Andrea Zachary And Dr. Mary Leffell To Its Medical Advisory Board As Co-Directors Of Science For Kidney Paired Donation

Expands Reach and Depth of BiologicTx Paired Donation™ and BiologicTx MatchGrid™

Jan 05, 2016, 15:05 ET from BiologicTx

TOTOWA, N.J., Jan. 5, 2016 /PRNewswire/ -- BiologicTx®, a transplant-focused specialty pharmacy, today appointed Andrea Z. Zachary, PhD, Diplomate, ABHI, and Mary S. Leffell, PhD, Diplomate, ABMLI, ABHI, to its Medical Advisory Board as Co-Directors of Science for the BiologicTx Kidney Paired Donation Program.  In their new role, Drs. Zachary and Leffell will work with BiologicTx's proprietary matching software, BiologicTx MatchGrid™ in several respects, including evaluating match runs between participating transplant centers, both domestically and internationally, and enhancing related software development. They join on the BiologicTx Medical Advisory Board Dr. Tim Taber, Chief of Transplant Nephrology, Medical Director of Kidney-Pancreas Transplant Program, and Medical Director of Living Donation - all at Indiana University Health Solid Organ Transplant.  Dr. Taber is also a Professor of Clinical Medicine at Indiana University.

"In accordance with our mission to provide the best possible care to transplant patients, we are thrilled to add Dr. Zachary and Dr. Leffell to our kidney paired donation team," said Sal Rafanelli, RPh, Chief Executive Officer, and Co-Founder of BiologicTx. "These two women offer unparalleled expertise not only in kidney paired donation, but also in the field of digital health and transplant desensitization, which are two strong and growing components of our business. We look forward to their contributions."

Dr. Andrea Zachary is Emeritus Professor of Medicine and former Director in the Division of Immunogenetics and Transplantation Immunology at Johns Hopkins University, School of Medicine where her primary interest was in the humoral response to allogeneic transplantation.  She was involved in the development of the protocol used at Johns Hopkins to desensitize potential transplant recipients who are immunologically incompatible with their donor. She is internationally recognized for her expertise in assessing the risk incurred by HLA specific antibodies and for her work on the differential immunogenicity of HLA antigens. Dr. Zachary has been involved in transplantation immunology and histocompatibility testing for more than 45 years and for more than 12 years in kidney paired donation at both Johns Hopkins and the National Kidney Registry (NKR).

Dr. Zachary has authored more than 150 articles and is a Past President of the American Society for Histocompatibility and Immunogenetics (ASHI), and was a member of the Board of Directors of UNOS, and a member of the program committee for the Surgeon General of the United States' Workshop on Organ Donation. 

Dr. Mary S. (Sue) Leffell is also Emeritus Professor of Medicine and former Director, Division of Immunogenetics and Transplantation Immunology at Johns Hopkins University.  Dr. Leffell's interests include population studies of the distribution of HLA alleles and haplotypes, minor histocompatibility antigens, KIR, and cytokine alleles among various racial/ethnic groups.  Her studies in transplantation immunology have included the effect of proinflammatory events and infection on the breadth and strength of HLA-specific antibodies among sensitized solid organ transplant candidates; the incidence of post-transplant sensitization following mismatched allogeneic hematopoietic cell transplantation (HCT); desensitization and subsequent successful engraftment of HCT candidates with donor HLA-specific antibodies; and the incidence and impact of HLA-specific alloimmunization among patients requiring transfusion support.

Dr. Leffell has worked in the field of clinical transplantation and histocompatibility for more than 35 years and involved in kidney paired donation for 15 years at Johns Hopkins, National Kidney Registry (NKR), and OPTN/UNOS. She has authored more than 150 articles and is a Past President of the American Society for Histocompatibility and Immunogenetics (ASHI). She has served on various boards and committees for OPTN/UNOS, and was a member of the Advisory Committee on Organ Transplantation to the Secretary of the Department of Health and Human Services from 2005 to 2009.

BiologicTx's Kidney Paired Donation program is led by Nancy Duncan, RN, BSN, CCTC, Director of Kidney Paired Donation at BiologicTx, working with the Chief Development Officer and Co-Founder of BiologicTx, Todd Krasinsky, RN.

For additional information regarding BiologicTx's Kidney Paired Donation Program, please visit or call us 877-567-8087.

About BiologicTx®
BiologicTx® is a national specialty pharmacy that joins the administration of therapeutics, research, and digital health to advance the practice of solid organ transplant and chronic specialties.  BiologicTx is comprised of four operating segments:

  • BiologicTx Pharmacy and Therapeutic Services
  • BiologicTx Clinical Trials™ - designs, sponsors, and aggregates clinical data
  • BiologicTx Discovery 2 Life™ - sponsors digital health platforms including BiologicTx Sequence™ and BiologicTx MatchGrid™
  • BiologicTx Paired Donation™ - offers an advanced software matching system, MatchGrid, supplying clinical decision intelligence to transplant centers.

For more information, visit us at:


Media Contact:

Tara Marchese



Logo -


SOURCE BiologicTx